Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
November 13, 2018First oral Rapid-Acting Antidepressant to be granted Breakthrough Designation
WILMINGTON, Del. - NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, has been granted...
-
September 5, 2018
WILMINGTON, Del., Sept. 05, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
September 4, 2018
WILMINGTON, De. , Sept. 04, 2018 -- NeuroRx, a clinical stage biopharma company developing NRX-101, the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation & Behavior...
-
June 11, 2018
WILMINGTON, Del. - NeuroRx, Inc., a clinical stage biopharma company has completed the feasibility enrollment phase of its 2b/3 clinical trial of NRX-101 for the treatment of suicidal bipolar...
-
May 7, 2018FDA deems proposed Phase 2b/3 trial adequate to support a regulatory submission
WILMINGTON, Del., May 07, 2018 -- NeuroRx, a clinical stage biopharmaceutical company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation...
-
January 3, 2018Company to present at J.P. Morgan Healthcare Conference in San Francisco January 10th, 2018
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat Severe Bipolar Depression in patients with Acute Suicidal Ideation & Behavior (ASIB), announced that it has...
-
December 27, 2017Third clinical research site for NRX-100 / NRX-101 phase 2B/3 clinical study
NeuroRx, a clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB), announced that it has...
-
September 6, 2017Company to present at Rodman and Renshaw Global Investment Conference in New York City on Sept 12, 2017
NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), has been granted Fast Track status by the US Food and Drug...
-
April 12, 2017Recent hospitalization is a risk factor for further suicide attempts -- potentially related to patient care perceptions
WILMINGTON, Del. - NeuroRx launches the first global “Voice of the Patient Survey” for those diagnosed with bipolar disorder, in collaboration with leading patient advocacy groups, mental...
-
March 24, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 24, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
March 19, 2017Company developing NRX-101 – first potential biomarker-based oral treatment for Acute Suicidal Ideation & Behavior in Bipolar Depression
Wilmington, Delaware , March 20, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today announced that...
-
February 10, 2017Company developing NRX-101 – first potential treatment for Acute Suicidal Ideation in Bipolar Depression
Wilmington, Delaware & Tel Aviv, Israel , Feb. 10, 2017 -- NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB), today...
-
January 4, 2017Clinical stage biopharma company advances development of first-in-class drug to decrease the risk of suicide in those suffering from bipolar depression
Biotech Showcase at the JP Morgan Healthcare Conference NeuroRx, a clinical stage biopharma company developing the first oral therapy for Acute Suicidal Ideation and Behavior (ASIB) in Bipolar...
-
December 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
December 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
December 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
October 18, 2016NeuroRx solidifies Intellectual Property Position - receives notice of Allowance by US Patent OfficeCompany with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression
NeuroRx, a clinical-stage pharmaceutical company developing NRX-101 (CycluradTM), a first-in-class potentially breakthrough oral drug for the treatment of Acute Suicidal Ideation in Bipolar...
-
September 7, 2016
NeuroRx, a clinical-stage pharmaceutical company developing CycluradTM, a first-in-class, potentially breakthrough drug for the prevention of suicide in bipolar depression, announced today that it...
-
June 1, 2016Company with research operations in US and Israel seeks to develop first-in-class drug to decrease the risk of suicide in those suffering from depression
TEL AVIV, Israel - NeuroRx, a clinical-stage pharmaceutical company developing a first-in-class potentially breakthrough drug for the prevention of suicide in bipolar depression, was awarded first...
-
October 21, 2015Findings note the transient nature of ketamine effects and paucity of promising experimental NMDA antagonists
The active ingredient of Cyclurad™ by NeuroRx, Inc has been identified as potentially promising in the treatment of depression in this month's report by the American Psychiatric Association Task...
-
June 24, 2015Journal of Clinical Psychiatry publishes initial report of human study which showed 50% reduction in symptoms of depression and 75% reduction in suicidality
NeuroRx, Inc., a clinical phase pharmaceutical company, reports first-in-man efficacy data for a newly-purposed class of drugs targeted towards rapidly reducing symptoms of depression and...
-
June 24, 2013Include multimedia assets in your release for better visibility
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi,...
-
March 1, 2011Use This To Test Potential Limitations With Your Site Design
ACME Inc. (NYSE: ) today reported financial results for the fourth quarter and full year ended December 31, 2010. For the fourth quarter 2010, we...
Click here to view our corporate presentation or on the image below